Clinical Trials Directory

Trials / Completed

CompletedNCT00947076

To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg

A Comparative Bioavailability Study of Fluoxetine Hydrochloride Capsules, 40 mg

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Sandoz · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.

Conditions

Interventions

TypeNameDescription
DRUGFluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
DRUGFluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Timeline

Start date
2001-02-01
Primary completion
2001-04-01
Completion
2001-04-01
First posted
2009-07-27
Last updated
2017-03-28

Source: ClinicalTrials.gov record NCT00947076. Inclusion in this directory is not an endorsement.

To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg (NCT00947076) · Clinical Trials Directory